<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="39015">Apolipoprotein</z:chebi> (apo)C-III is a constituent of <z:chebi fb="17" ids="39025">HDL</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi> apoC-III) and of apoB-containing <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> (LpB:C-III) </plain></SENT>
<SENT sid="1" pm="."><plain>It slows the clearance of <z:chebi fb="0" ids="17855">triglyceride</z:chebi>-rich <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> (TRLs) by inhibition of the activity of the enzyme <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> lipase (LPL) and by interference with <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> binding to cell-surface receptors </plain></SENT>
<SENT sid="2" pm="."><plain>Elevated plasma LpB:C-III is an independent risk factor for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We studied the effect of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> on plasma LpB:C-III and <z:chebi fb="17" ids="39025">HDL</z:chebi> apoC-III </plain></SENT>
<SENT sid="4" pm="."><plain>RESEARCH DESIGN AND METHODS: We studied the effect of 30 weeks' treatment with 10 and 80 mg <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> on plasma apoC-III levels in a randomized, double-blind, placebo-controlled trial involving 217 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and fasting plasma <z:chebi fb="4" ids="17855">triglycerides</z:chebi> between 1.5 and 6.0 mmol/l </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Baseline levels of total plasma apoC-III, <z:chebi fb="17" ids="39025">HDL</z:chebi> apoC-III, and LpB:C-III were 41.5 +/- 10.0, 17.7 +/- 5.5, and 23.8 +/- 7.7 mg/l, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Plasma apoC-III was strongly correlated with plasma <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (r = 0.74, P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> 10- and 80-mg treatment significantly decreased plasma apoC-III (<z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 mg, 21%, and 80 mg, 27%), <z:chebi fb="17" ids="39025">HDL</z:chebi> apoC-III (<z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 mg, 22%, and 80 mg, 28%) and LpB:C-III (<z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 mg, 23%, and 80 mg, 28%; <z:hpo ids='HP_0000001'>all</z:hpo> P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>The decrease in plasma apoC-III, mainly in LpB:C-III, strongly correlated with a decrease in <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (<z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 mg, r = 0.70, and 80 mg, r = 0.78; P &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> treatment also leads to a reduction in the <z:chebi fb="17" ids="39025">HDL</z:chebi> apoC-III-to-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> and <z:chebi fb="17" ids="39025">HDL</z:chebi> apoC-III-to-apoA-I ratios, indicating a change in the number of apoC-III per <z:chebi fb="17" ids="39025">HDL</z:chebi> particle (<z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 mg, -21%, and 80 mg, -31%; P &lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> treatment resulted in a significant dose-dependent reduction in plasma apoC-III, <z:chebi fb="17" ids="39025">HDL</z:chebi> apoC-III, and LpB:C-III levels in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>These data indicate a potentially important antiatherogenic effect of <z:chebi fb="0" ids="35664">statin</z:chebi> treatment and may explain (part of) the <z:chebi fb="0" ids="17855">triglyceride</z:chebi>-lowering effect of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> </plain></SENT>
</text></document>